Pharmalot… Pharmalittle… Good Morning
1 CommentBy Ed Silverman // November 16th, 2010 // 8:12 am
Rise and shine. Another day is on the way. Although, clouds are hovering over the Pharmalot corporate campus. Nonetheless, we are reminded, once again, of what the Morning Mayor would say: ‘Every brand new day should be unwrapped like a precious gift.’ We urge you to tug on the ribbon. And, of course, please join us for a cup of stimulation and the news of the world. Have a great day, everyone…
Docs Say Bloodthinner Race Is Too Close To Call (Reuters)
Patent Upheld On Bristol-Myers Abilify Schizophrenia Med (Bloomberg News)
Value-Based Pricing Is No Magic Bullet: ABPI (InPharm)
FDA Approves Eisai Med For Breast Cancer (Bloomberg News)
Pfizer Signs R&D Deal With UC San Francisco (The Wall Street Journal)
Merck Loses 50 Execs In India (The Economic Times)
Lupus Drug To Be Reviewed By FDA Panel (Raleigh News & Observer)
USP Builds A Database Of Counterfeit Meds (InPharma-Technologist)
Shire ADHD Drug Approved For Teens (Philadelphia Business Journal)
Australian Pharma Clash Over Drug Price Disclosure Law (Outsourcing Pharma)
Litigation Over Epilepsy Drug Placed On Hold (UK Press Association)
Condor
Thanks, Ed — the Merck India story is interesting: it has developed over the past 48 hours — with new (albeit off-the-record) sources in at least one paper — suggesting that at least some of the 50 “Refusnik” legacy Schering-Plough executives in India were actually fired, for compliance violations.
I’ll let the readership know whatever subsequently turns up.
Namaste